Ibalizumab
Based on 1 Customer Validation
Ibalizumab (TMB-355) is a humanized anti-CD4 IgG4 monoclonal antibody. Ibalizumab prevents HIV cell entry by binding to CD4 receptor. Ibalizumab can be used for the research of infection, such as HIV-1 infection.
For research use only. We do not sell to patients.
- Purity : 99.74%
- CAS No.: 680188-33-4
- Molecular Weight:147.36 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
HIV-1 |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Humanized mouse model (NDG-HuPBL) with HIV-1CH058 infection[1]
-
Dosage:400 μg/mouse
-
Administration:Intraperitoneally injection, at days 1, 3, 5 and 7
-
Result:Reduced viral loads.
Reduced P24+ positive cells.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized huCD4-ECD can bind Ibalizumab. The EC50 for this effect is 3.922 ng/mL. -
Flow cytometric analysis of 1.5X106 THP-1 cells with Ibalizumab (HY-P99028, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control.
Chemical Information
-
CAS No. 680188-33-4
-
Appearance Liquid
-
Molecular Weight 147.36 kDa
-
Color Colorless to light yellow
-
SMILES
[Ibalizumab]
-
Synonyms
TMB-355; TNX-355
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Zhu L, et al. Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration. Nat Commun. 2024 Aug 13;15(1):6961. [Content Brief]
[2]. Beccari MV, et al. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection. Antimicrob Agents Chemother. 2019 May 24;63(6):e00110-19. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)